Gomekli (mirdametinib) - EMD Serono
Stivarga (regorafenib) - Bayer
Mekinist (trametinib) - Novartis, BeOne Medicines
Genetic evidence and multi-omics characterization of DEHP-relevant detoxification and metabolic heterogeneity in hepatocellular carcinoma. (PubMed, Front Toxicol) - Oct 15, 2026 - "LINCS-based screening and molecular docking prioritized PD-0325901, trametinib, and regorafenib, but these predictions did not demonstrate binding or efficacy, and the compounds were not tested experimentally. DPTS defines a DEHP-relevant, detoxification-suppressed HCC molecular phenotype rather than an exposure-defined or DEHP-induced subtype. These findings provide a bounded framework for future mechanistic validation of metabolic vulnerability in HCC." 
Heterogeneity • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • ALDH2 • EHHADH
http://www.ncbi.nlm.nih.gov/pubmed/42871276
 
Guoqing Zhang; Letian Ren; Wence Zhou; Zeyang Fan
 
Oct 15, 2026
 
Prev Next